Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study.


Journal

Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875

Informations de publication

Date de publication:
04 2019
Historique:
received: 14 09 2018
accepted: 12 01 2019
pubmed: 30 1 2019
medline: 30 1 2020
entrez: 30 1 2019
Statut: ppublish

Résumé

Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV ("pre-2011"), A-D ("2011-2016") and A-D ("2017-present") in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD "pre-2011", "2011-2016" and "2017-present" classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D "2011-2016" classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D "2017-present" classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD "2017-present" system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D "2017-present" scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.

Identifiants

pubmed: 30694380
doi: 10.1007/s00408-019-00196-6
pii: 10.1007/s00408-019-00196-6
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-179

Références

Chest. 2003 Aug;124(2):459-67
pubmed: 12907529
Eur Respir J. 2013 Nov;42(5):1391-401
pubmed: 23645406
Eur Respir J. 2017 Apr 26;49(4):
pubmed: 28446560
Am J Respir Crit Care Med. 2012 Nov 15;186(10):975-81
pubmed: 22997207
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Thorax. 2005 Nov;60(11):925-31
pubmed: 16055622
Int J Chron Obstruct Pulmon Dis. 2018 Mar 26;13:1037-1052
pubmed: 29628761
Am J Respir Crit Care Med. 2018 Feb 15;197(4):463-469
pubmed: 29099607
Chest. 2002 May;121(5):1441-8
pubmed: 12006426
Eur Respir J. 2013 Sep;42(3):636-46
pubmed: 23766334
Int J Chron Obstruct Pulmon Dis. 2014 Nov 10;9:1265-74
pubmed: 25419124
Arch Bronconeumol. 2017 Jun;53(6):324-335
pubmed: 28477954
Int J Chron Obstruct Pulmon Dis. 2018 May 01;13:1433-1439
pubmed: 29750029
Eur Respir J. 2017 May 11;49(5):
pubmed: 28495687

Auteurs

Marek Plutinsky (M)

Department of Respiratory Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 62500, Brno, Czech Republic.

Kristian Brat (K)

Department of Respiratory Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 62500, Brno, Czech Republic. kristian.brat@seznam.cz.

Michal Svoboda (M)

Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.

Jaromir Zatloukal (J)

Pulmonary Department, University Hospital Olomouc and Faculty of Medicine, Palacky University, Olomouc, Czech Republic.

Patrice Popelkova (P)

Pulmonary Department, University Hospital Ostrava, Ostrava, Czech Republic.

Vladimir Koblizek (V)

Pulmonary Department, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH